NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
6 January 2025
HOOKIPA Pharma Inc.
(“HOOKIPA”)
Rule 2.9 Announcement – Amendment
NEW YORK and VIENNA, Austria, Jan. 06, 2025 (GLOBE NEWSWIRE) — The following amendment has been made to the ‘Rule 2.9 Information’ disclosed by HOOKIPA in the Rule 2.4 announcement made on 2 January 2025 regarding the potential combination of HOOKIPA and Poolbeg Pharma plc (the “Rule 2.4 Announcement”).
The ISIN of HOOKIPA’s common stock was incorrectly stated in the Rule 2.4 Announcement as US43906K1007. The correct ISIN of the common stock is US43906K2096, which became effective following the completion of HOOKIPA’s 1-for-10 reverse stock split on 9 July 2024. All other details remain unchanged.
The full text of the Rule 2.9 Information relating to HOOKIPA is reproduced below, as amended.
In accordance with Rule 2.9 of the Code, and further to the announcement made on 2 January 2025, HOOKIPA confirms that it has 9,655,022 shares of common stock of $0.0001 par value per share each in issue (“Common Stock”). The ISIN Code of the Common Stock is US43906K2096.
In addition to its Common Stock, HOOKIPA confirms that it has in issue 2,399,517 shares of Class A common stock, 370 shares of Series A convertible preferred stock, 10,800 shares of Series A-1 convertible preferred stock, and 15,268 shares of Series A-2 convertible preferred stock outstanding.
Each holder of Class A common stock has the right to convert each ten shares of Class A common stock into one share of Common Stock at such holder’s election, provided that the holder will be prohibited, subject to certain exceptions, from converting Class A common stock into shares of Common Stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of Common Stock then issued and outstanding. Each holder of Series A, Series A-1 and Series A-2 convertible preferred stock has the right to convert each share of Series A, Series A-1 and Series A-2 convertible preferred stock into 100 shares of Common Stock at any time at the holder’s option, provided that the holder will be prohibited, subject to certain exceptions, from converting Series A, Series A-1 and Series A-2 convertible preferred stock into shares of Common Stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of Common Stock then issued and outstanding.
HOOKIPA has also granted 369,070 shares of Common Stock in the form of restricted stock units to certain individuals pursuant to its incentive plans.
HOOKIPA does not hold any ‘Relevant Securities’ (within the meaning of the Code) in treasury.
| Enquiries: | |
| HOOKIPA Pharma Inc. | +43 1 890 63 60 |
| Malte Peters, CEO Terry Coelho, EVP & CFO | IR@hookipapharma.com Chuck@LifeSciAdvisors.com |
| Moelis & Company (Financial Adviser to HOOKIPA) | +44 (0) 207 634 3500 |
| London Chris Raff Simon Chaudhuri New York Ashish Contractor | |
Important information
This announcement is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities whether pursuant to this announcement or otherwise.
The distribution of this announcement in jurisdictions outside the United Kingdom may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves about, and observe such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction.
Moelis & Company LLC (“Moelis”) is acting as financial adviser to HOOKIPA in connection with the matters set out in this announcement and for no one else and will not be responsible to anyone other than HOOKIPA for providing the protections afforded to its clients nor for providing advice in relation to the matters set out in this announcement. Neither Moelis nor any of its subsidiaries, branches or affiliates and their respective directors, officers, employees or agents owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Moelis in connection with this announcement, any statement contained herein or otherwise.
Disclosure requirements of the Takeover Code (the “Code”)
Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person’s interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.
Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person’s interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.
If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3. Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).
Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel’s website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel’s Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.
This press release was published by a CLEAR® Verified individual.
- Oliveda International, Inc. (OLVI) Subsidiary Olive Tree People Canada Inc. Brings Its Waterless Beauty to Canada in July 2025 - June 30, 2025
- Western Uranium & Vanadium Announces Results of AGM and Appoints New Transfer Agent - June 30, 2025
- Welcome Reception to Kick Off 2025 Central Florida Business Expo with Innovation and Regional Collaboration - June 30, 2025
